No Result
View All Result
SUBSCRIBE | NO FEES, NO PAYWALLS
MANAGE MY SUBSCRIPTION
NEWSLETTER
Corporate Compliance Insights
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe
No Result
View All Result
Corporate Compliance Insights
Home Fraud

The Shoe Drops on Theranos’ Former CEO and COO

by Michael Volkov
June 20, 2018
in Fraud
elizabeth holmes of theranos

Criminal Indictment Filed Charging Fraud

The fallout continues for Elizabeth Holmes and Sunny Balwani, respectively the CEO and COO of Theranos. The pair were charged with fraud by the SEC and were indicted last week on wire fraud and conspiracy charges. Michael Volkov reviews the cautionary tale of Theranos, outlining many of the ways Theranos defrauded investors and health care professionals.

Sometimes a fraudster is just a fraudster. They are dangerous because they can manipulate without remorse or conscience. The rise and fall of Elizabeth Holmes and Theranos is a classic story of a manipulative CEO engaged in nothing more than a classic fraud.

Holmes was once the Silicon Valley star who claimed to be a billionaire.  Her fortunes started to unravel quickly following a Wall Street Journal investigative report that uncovered massive fraud at Theranos in late 2015.  Seven months later, Theranos announced that its blood test results for the past two years were “void.”

Holmes settled SEC charges of fraud earlier this year for $50 million. Ramesh “Sunny” Balwani, the company’s former COO, was also charged, and his case is still pending.

Last Friday, the criminal shoe dropped on Silicon Valley’s glamour CEO and COO with the filing of charges against Elizabeth Holmes, the former CEO, and Balwani.  They were each charged with two counts of conspiracy to commit wire fraud and nine counts of wire fraud relating to Theranos, the company that claimed it would revolutionize medical laboratory testing of blood. (Read the indictment here).

Holmes founded the company in 2003.  Balwani worked at Theranos from 2009 to 2016.  As alleged in the indictment, Holmes and Balwani defrauded investors and health care professionals as to Theranos’ claimed new technology for collecting, testing and interpreting blood samples.

Following the basic maxim, Holmes made claims that were simply too good to be true.  She claimed that Theranos had developed a new technology that would allow quick blood tests to be completed based on a small sample, even a pinprick of blood, that would be more reliable and effective than conventional blood-testing products.

Prior to the launch of the company in 2013, Holmes and Balwani unleashed a torrent of marketing to convince investors of Theranos’ revolutionary new technology and focused their efforts on physicians and patients. Their communications were loaded with false claims and assertions that they knew were false.

The government’s indictment claims that Holmes and Balwani falsely advertised and solicited doctors and patients to use Theranos’ blood-testing laboratory services, knowing that Theranos was not capable of producing accurate and reliable results for certain blood tests.

Further, and as a separate conspiracy, the indictment alleges that Holmes and Balwani used a large number of false direct communications, marketing materials, statements to the media, financial statements and models to defraud investors about the accuracy and reliability of Theranos’ technology.

The defendants claimed that Theranos’ analyzer, referred to by various names such as TPSU, Edison and minilab, was able to perform a full range of clinical tests using small blood samples drawn from a finger stick. They also claimed that this technology produced results that were more reliable than those from conventional methods.

Holmes and Balwani knew that these claims were, in fact, false – specifically, the indictment claims they knew that the analyzer had accuracy and reliability problems, performed only a small number of tests and was slower than competing devices.

The defendants knew that Theranos was delivering to doctors and patients blood results that were inaccurate, unreliable and improperly validated. Theranos also regularly removed critical blood test results when providing results to doctors and patients.

The defendants also made numerous misrepresentations to potential investors about Theranos’ financial condition and its future prospects. For example, the indictment references the defendants’ representation to investors that Theranos conducted its tests using Theranos-manufactured analyzers, when in fact, Holmes and Balwani knew that Theranos purchased and used competitors’ commercially available analyzers to conduct the tests.

The defendants also claimed that Theranos would generate $100 million in revenues in 2014 and $1 billion in 2015 but knew that actual results would be negligible or modest, at best, for both years. The defendants falsely claimed that Theranos had valuable contracts with the U.S. Department of Defense to deploy its testing analyzer on the battlefield, when in fact, the Department of Defense had no plans to use the analyzer on the battlefield.

Theranos had established a relationship with Walgreens and planned to participate in the establishment of Walgreens’ Wellness Centers. Holmes and Balwani specifically claimed that Theranos would dramatically increase the number of Wellness Centers in Walgreens; in fact, they knew by late 2014 that Theranos’ retail rollout at Walgreens stalled because of Walgreen’s concerns with Theranos’ performance.

Holmes and Balwani falsely claimed that Theranos did not need FDA approval for its new technology while simultaneously seeking approval from the FDA as required under applicable law and regulations.

This article was republished with permission from Michael Volkov’s blog, Corruption, Crime & Compliance.


Tags: Health CareSECTheranos
Previous Post

Moving From Reports to Analytics

Next Post

TRACE: Debating ISO 37001

Michael Volkov

Michael Volkov

Michael-Volkov-leclairryan Michael Volkov is the CEO of The Volkov Law Group LLC, where he provides compliance, internal investigation and white collar defense services.  He can be reached at mvolkov@volkovlaw.com. Michael has extensive experience representing clients on matters involving the Foreign Corrupt Practices Act, the UK Bribery Act, money laundering, Office of Foreign Asset Control (OFAC), export controls, sanctions and International Traffic in Arms, False Claims Act, Congressional investigations, online gambling and regulatory enforcement issues. Michael served for more than 17 years as a federal prosecutor in the U.S. Attorney’s Office in the District of Columbia; for five years as the Chief Crime and Terrorism Counsel for the Senate Judiciary Committee, and Chief Crime, Terrorism and Homeland Security Counsel for the Senate and House Judiciary Committees; and as a Trial Attorney in the Antitrust Division of the U.S. Department of Justice. Michael also maintains a well-known blog: Corruption Crime & Compliance, which is frequently cited by anti-corruption professionals and professionals in the compliance industry.

Related Posts

volkov tea leaves fcpa enforcement

Reading the Tea Leaves: FCPA Enforcement Trends Send Mixed Signals

by Michael Volkov
June 15, 2022

Though it’s taken a while to gain steam, the Biden Administration’s approach to FCPA enforcement is becoming clearer. But as...

test image for new AR

When It Comes to Climate Disclosures, SEC and FTC Speak Different Languages

by Tony Subketkaew
May 11, 2022

Expanded climate reporting will likely tempt marketing teams to try to capitalize on favorable climate performance as disclosed in reporting....

QA logo seery mike

Q&A: The SEC Would Love to Regulate Cryptocurrencies, But So Far, Their Efforts Are Hobbled. What’s the Current and Future State for Investment Managers?

by Bill Millar
April 20, 2022

President Joe Biden signed an executive order March 9 intended to instill consumer protection and financial stability, prevent illicit uses...

greenhouse gas emissions cloud

SEC is Poised to Clear the Air on ESG Reporting. That Means Your Company Has Less Than Six Months to Prepare.

by Karen Alonardo
April 13, 2022

Standardized rule-making on climate disclosures has lagged in the U.S. But no more. Observers like Karen Alonardo of NAVEX Global...

Next Post
ISO 37001 badge

TRACE: Debating ISO 37001

Compliance Job Interview Q&A

Jump to a Topic

AML Anti-Bribery Anti-Corruption Artificial Intelligence (AI) Automation Banking Board of Directors Board Risk Oversight Business Continuity Planning California Consumer Privacy Act (CCPA) Communications Management Corporate Culture COVID-19 Cryptocurrency Culture of Ethics Cybercrime Cyber Risk Data Analytics Data Breach Data Governance Decision-Making DOJ Download Due Diligence Enterprise Risk Management (ERM) ESG FCPA Enforcement Actions Financial Crime GDPR HIPAA Know Your Customer (KYC) Machine Learning Monitoring Ransomware RegTech Reputation Risk Risk Assessment SEC Social Media Risk Supply Chain Technology Third Party Risk Management Tone at the Top Training Whistleblowing
No Result
View All Result

Privacy Policy

Founded in 2010, CCI is the web’s premier global independent news source for compliance, ethics, risk and information security. 

Got a news tip? Get in touch. Want a weekly round-up in your inbox? Sign up for free. No subscription fees, no paywalls. 

Follow Us

Browse Topics:

  • CCI Press
  • Compliance
  • Compliance Podcasts
  • Cybersecurity
  • Data Privacy
  • eBooks Published by CCI
  • Ethics
  • FCPA
  • Featured
  • Financial Services
  • Fraud
  • Governance
  • GRC Vendor News
  • HR Compliance
  • Internal Audit
  • Leadership and Career
  • On Demand Webinars
  • Opinion
  • Resource Library
  • Risk
  • Uncategorized
  • Videos
  • Webinars
  • Well-Being
  • Whitepapers

© 2022 Corporate Compliance Insights

No Result
View All Result
  • Home
  • About
    • About CCI
    • Writing for CCI
    • NEW: CCI Press – Book Publishing
    • Advertise With Us
  • Explore Topics
    • See All Articles
    • Compliance
    • Ethics
    • Risk
    • FCPA
    • Governance
    • Fraud
    • Internal Audit
    • HR Compliance
    • Cybersecurity
    • Data Privacy
    • Financial Services
    • Well-Being at Work
    • Leadership and Career
    • Opinion
  • Vendor News
  • Career Connection
  • Events
    • Calendar
    • Submit an Event
  • Library
    • Whitepapers & Reports
    • eBooks
    • CCI Press & Compliance Bookshelf
  • Podcasts
  • Videos
  • Subscribe

© 2022 Corporate Compliance Insights

Welcome to CCI. This site uses cookies. Please click OK to accept. Privacy Policy
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT